{
    "clinical_study": {
        "@rank": "46759", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration)."
            }, 
            {
                "arm_group_label": "Treatment B", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration)."
            }, 
            {
                "arm_group_label": "Treatment C", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration)."
            }, 
            {
                "arm_group_label": "Treatment D", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration)."
            }
        ], 
        "brief_summary": {
            "textblock": "To estimate the pharmacokinetics and relative bioavailability of oxycodone after\n      administration of 40 mg doses of PF-00345439 formulations taken whole under fed conditions\n      and after chewing under fasted conditions in healthy volunteers"
        }, 
        "brief_title": "Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female subjects between 18 and 55 years of age (inclusive).\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant disease.\n\n          -  Positive urine drug test"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "19", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01717027", 
            "org_study_id": "B4501034"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment A", 
                "description": "One capsule of 40 mg PF-00345439 Formulation A, single dose, taken whole and under fed conditions", 
                "intervention_name": "Oxycodone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "description": "One capsule of 40 mg PF-00345439 Formulation J, single dose, taken whole and under fed conditions", 
                "intervention_name": "Oxycodone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment C", 
                "description": "One capsule of 40 mg PF-00345439 Formulation K, single dose, taken whole and under fed conditions", 
                "intervention_name": "Oxycodone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment D", 
                "description": "One capsule of 40 mg PF-00345439 Formulation J or K, single dose, chewed and under fasted conditions", 
                "intervention_name": "Oxycodone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Oxycodone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "pharmacokinetics", 
            "bioavailability", 
            "oxycodone", 
            "management of moderate to severe pain"
        ], 
        "lastchanged_date": "April 15, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4501034&StudyName=Pharmacokinetics%20And%20Relative%20Bioavailability%20Study%20Of%20Oxycodone%20in%20Healthy%20Volunteers%0A"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Open Label, Single Dose, Randomized, Crossover Study To Evaluate The Pharmacokinetics And Relative Bioavailability Of Oxycodone Following Oral Administration Of 40 Mg Doses Of PF 00345439 Taken Whole Under Fed Conditions And After Chewing Under Fasted Conditions In Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) (if data permit, otherwise Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUClast]) of oxycodone.", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01717027"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of oxycodone, as data permit", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of oxycodone, as data permit.", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose"
            }, 
            {
                "measure": "Plasma Decay Half-Life of oxycodone, as data permit.", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose"
            }, 
            {
                "measure": "Concentration at time 24 hours (C24) of oxycodone, as data permit.", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}